Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jan;52(1):5-8.
doi: 10.1111/cup.14684. Epub 2024 Jul 10.

Acantholytic PRIDE syndrome

Biswanath Behera  1 , Ashish Kumar Nayak  1 , Siddhartha Dash  1 , Madhusmita Sethy  2 , Pavithra Ayyanar  2
Affiliations

Acantholytic PRIDE syndrome

Biswanath Behera et al. J Cutan Pathol. 2025 Jan.
No abstract available

PubMed Disclaimer

References

REFERENCES

    1. Madke B, Gole P, Kumar P, Khopkar U. Dermatological side effects of epidermal growth factor receptor inhibitors: ‘PRIDE’ complex. Indian J Dermatol. 2014;59(3):271‐274. doi:10.4103/0019‐5154.131398
    1. Wnorowski AM, de Souza A, Chachoua A, Cohen DE. The management of EGFR inhibitor adverse events: a case series and treatment paradigm. Int J Dermatol. 2012;51(2):223‐232. doi:10.1111/j.1365‐4632.2011.05082.x
    1. Pavey RA, Kambil SM, Bhat RM. Dermatological adverse reactions to cancer chemotherapy. Indian J Dermatol Venereol Leprol. 2015;81(4):434. doi:10.4103/0378‐6323.159950
    1. Thakur V, Daroach M, Kumaran MS. Papulopustules and paronychia in a lung carcinoma. Eur J Intern Med. 2019;62:e5‐e6. doi:10.1016/j.ejim.2018.09.022
    1. Saini K, Sutaria A, Shah B, Brahmbhatt V, Parmar K. Cutaneous adverse drug reactions to targeted chemotherapeutic drugs: a clinico‐epidemiological study. Indian J Dermatol. 2019;64(6):471‐475. doi:10.4103/ijd.IJD_491_18

LinkOut - more resources